Ceptaris, a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.

Based upon results of a recently completed trial, Ceptaris intends to file a new drug application (NDA) with the Food and Drug Administration (FDA) in 2011. If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Ceptaris has augmented its management team with the addition of a number of experienced pharmaceutical executives as it approaches regulatory filing and potential commercialization of mechlorethamine gel.